Focus Partners Wealth Raises Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Focus Partners Wealth raised its stake in Thermo Fisher by 1.2% in Q3, ending the period with 258,747 shares worth about $125.5 million.
• Thermo Fisher beat quarterly estimates with $6.57 EPS vs. $6.45 expected and revenue of $12.22 billion (up 7.2% year-over-year), and analysts project strong full‑year earnings.
• The company increased its quarterly dividend to $0.47 (annualized $1.88, 0.4% yield), while Wall Street sentiment is broadly positive with a consensus "Moderate Buy" and an average price target of $633.68 (some targets up to $700).

Focus Partners Wealth raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 258,747 shares of the medical research company's stock after purchasing an additional 2,947 shares during the quarter. Focus Partners Wealth owned 0.07% of Thermo Fisher Scientific worth $125,514,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Highline Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 126.9% in the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company's stock worth $29,000 after buying an additional 33 shares during the last quarter. Capital A Wealth Management LLC raised its position in Thermo Fisher Scientific by 825.0% during the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company's stock valued at $30,000 after acquiring an additional 66 shares in the last quarter. Cloud Capital Management LLC acquired a new position in Thermo Fisher Scientific in the third quarter valued at approximately $31,000. Howard Hughes Medical Institute purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth approximately $33,000. Finally, Elevation Wealth Partners LLC grew its stake in shares of Thermo Fisher Scientific by 35.1% during the 3rd quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company's stock worth $37,000 after purchasing an additional 20 shares during the period. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $463.99 on Monday. The business's 50 day moving average price is $557.83 and its 200 day moving average price is $549.01. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. The company has a market cap of $172.36 billion, a price-to-earnings ratio of 26.15, a PEG ratio of 2.68 and a beta of 0.96. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The firm had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.95 billion. During the same quarter in the prior year, the firm posted $6.10 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 7.2% on a year-over-year basis. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th will be paid a $0.47 dividend. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is presently 10.60%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. This represents a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Citigroup upped their price objective on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a "buy" rating in a research report on Friday, January 30th. Stifel Nicolaus lifted their price target on Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a "buy" rating in a research note on Friday, January 9th. Morgan Stanley increased their price target on Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 2nd. TD Cowen dropped their price objective on Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating on the stock in a report on Friday, January 30th. Finally, The Goldman Sachs Group initiated coverage on Thermo Fisher Scientific in a research note on Tuesday, December 9th. They set a "buy" rating and a $685.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $633.68.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.